JP2008512394A - Eph受容体を調節することによる神経系内のグリオーシス、グリア瘢痕、炎症、または軸索成長阻害の処置 - Google Patents
Eph受容体を調節することによる神経系内のグリオーシス、グリア瘢痕、炎症、または軸索成長阻害の処置 Download PDFInfo
- Publication number
- JP2008512394A JP2008512394A JP2007530543A JP2007530543A JP2008512394A JP 2008512394 A JP2008512394 A JP 2008512394A JP 2007530543 A JP2007530543 A JP 2007530543A JP 2007530543 A JP2007530543 A JP 2007530543A JP 2008512394 A JP2008512394 A JP 2008512394A
- Authority
- JP
- Japan
- Prior art keywords
- epha4
- substance
- nervous system
- receptor
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010018341 Gliosis Diseases 0.000 title claims abstract description 84
- 102000050554 Eph Family Receptors Human genes 0.000 title claims abstract description 57
- 108091008815 Eph receptors Proteins 0.000 title claims abstract description 57
- 230000007387 gliosis Effects 0.000 title claims abstract description 44
- 206010061218 Inflammation Diseases 0.000 title claims abstract description 32
- 230000004054 inflammatory process Effects 0.000 title claims abstract description 32
- 230000003376 axonal effect Effects 0.000 title claims abstract description 28
- 210000000653 nervous system Anatomy 0.000 title claims abstract description 24
- 206010061431 Glial scar Diseases 0.000 title claims abstract description 20
- 230000009036 growth inhibition Effects 0.000 title claims abstract description 8
- 238000011282 treatment Methods 0.000 title description 10
- 238000000034 method Methods 0.000 claims abstract description 107
- 230000001404 mediated effect Effects 0.000 claims abstract description 46
- 230000011664 signaling Effects 0.000 claims abstract description 33
- 210000000278 spinal cord Anatomy 0.000 claims abstract description 33
- 210000003169 central nervous system Anatomy 0.000 claims abstract description 29
- 239000003814 drug Substances 0.000 claims abstract description 20
- 108010055179 EphA4 Receptor Proteins 0.000 claims description 115
- 102000021727 EphA4 Receptor Human genes 0.000 claims description 115
- 239000000126 substance Substances 0.000 claims description 106
- 210000004027 cell Anatomy 0.000 claims description 45
- 150000007523 nucleic acids Chemical class 0.000 claims description 40
- 102000039446 nucleic acids Human genes 0.000 claims description 38
- 108020004707 nucleic acids Proteins 0.000 claims description 38
- 239000005557 antagonist Substances 0.000 claims description 29
- 230000008929 regeneration Effects 0.000 claims description 29
- 238000011069 regeneration method Methods 0.000 claims description 29
- 230000000692 anti-sense effect Effects 0.000 claims description 22
- 108020004999 messenger RNA Proteins 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 108091030071 RNAI Proteins 0.000 claims description 13
- 230000009368 gene silencing by RNA Effects 0.000 claims description 13
- 239000003937 drug carrier Substances 0.000 claims description 7
- 229940122293 Ephrin antagonist Drugs 0.000 claims description 6
- 230000012010 growth Effects 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 6
- 210000004498 neuroglial cell Anatomy 0.000 claims description 5
- 208000001738 Nervous System Trauma Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 3
- 208000028412 nervous system injury Diseases 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229940044551 receptor antagonist Drugs 0.000 claims description 2
- 239000002464 receptor antagonist Substances 0.000 claims description 2
- 230000037390 scarring Effects 0.000 claims description 2
- 230000006378 damage Effects 0.000 abstract description 84
- 208000014674 injury Diseases 0.000 abstract description 78
- 208000027418 Wounds and injury Diseases 0.000 abstract description 76
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 22
- 201000010099 disease Diseases 0.000 abstract description 18
- 229940124597 therapeutic agent Drugs 0.000 abstract description 10
- 210000004556 brain Anatomy 0.000 abstract description 8
- 208000012902 Nervous system disease Diseases 0.000 abstract description 7
- 206010033799 Paralysis Diseases 0.000 abstract description 4
- 208000035475 disorder Diseases 0.000 abstract description 4
- 230000001575 pathological effect Effects 0.000 abstract description 3
- 239000003576 central nervous system agent Substances 0.000 abstract description 2
- 229940125693 central nervous system agent Drugs 0.000 abstract description 2
- 230000008736 traumatic injury Effects 0.000 abstract 1
- 210000001130 astrocyte Anatomy 0.000 description 52
- 108090000765 processed proteins & peptides Proteins 0.000 description 51
- 150000001875 compounds Chemical class 0.000 description 45
- 102000012803 ephrin Human genes 0.000 description 43
- 108060002566 ephrin Proteins 0.000 description 43
- 241000699670 Mus sp. Species 0.000 description 37
- 210000003050 axon Anatomy 0.000 description 36
- 108090000623 proteins and genes Proteins 0.000 description 33
- 102000004196 processed proteins & peptides Human genes 0.000 description 32
- 230000014509 gene expression Effects 0.000 description 27
- 238000002347 injection Methods 0.000 description 25
- 239000007924 injection Substances 0.000 description 25
- 239000000203 mixture Substances 0.000 description 25
- 125000003729 nucleotide group Chemical group 0.000 description 25
- 230000006870 function Effects 0.000 description 24
- 239000002773 nucleotide Substances 0.000 description 24
- 108091034117 Oligonucleotide Proteins 0.000 description 22
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 21
- 210000002569 neuron Anatomy 0.000 description 21
- 239000003446 ligand Substances 0.000 description 20
- 229920001184 polypeptide Polymers 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 18
- 208000020431 spinal cord injury Diseases 0.000 description 18
- 235000001014 amino acid Nutrition 0.000 description 17
- 230000004913 activation Effects 0.000 description 16
- 150000001413 amino acids Chemical class 0.000 description 16
- 230000027455 binding Effects 0.000 description 16
- 235000018102 proteins Nutrition 0.000 description 15
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 230000005764 inhibitory process Effects 0.000 description 14
- 210000002241 neurite Anatomy 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 13
- 238000009472 formulation Methods 0.000 description 13
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 12
- 238000009396 hybridization Methods 0.000 description 12
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 11
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 11
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 11
- 230000004048 modification Effects 0.000 description 11
- 238000012986 modification Methods 0.000 description 11
- 230000014511 neuron projection development Effects 0.000 description 11
- 108091033319 polynucleotide Proteins 0.000 description 11
- 102000040430 polynucleotide Human genes 0.000 description 11
- 239000002157 polynucleotide Substances 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 10
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 10
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 230000014616 translation Effects 0.000 description 10
- 101800001318 Capsid protein VP4 Proteins 0.000 description 9
- 102100027609 Rho-related GTP-binding protein RhoD Human genes 0.000 description 9
- 238000011161 development Methods 0.000 description 9
- 230000018109 developmental process Effects 0.000 description 9
- 239000002502 liposome Substances 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 238000006722 reduction reaction Methods 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 238000013519 translation Methods 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 230000001969 hypertrophic effect Effects 0.000 description 7
- 230000033001 locomotion Effects 0.000 description 7
- 239000002777 nucleoside Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 235000000346 sugar Nutrition 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 230000028600 axonogenesis Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000000835 fiber Substances 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 230000026731 phosphorylation Effects 0.000 description 6
- 238000006366 phosphorylation reaction Methods 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000001172 regenerating effect Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 230000036573 scar formation Effects 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 238000012744 immunostaining Methods 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 210000003141 lower extremity Anatomy 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 150000003833 nucleoside derivatives Chemical class 0.000 description 5
- 229910052698 phosphorus Inorganic materials 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 210000000463 red nucleus Anatomy 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- -1 thiol compounds Chemical class 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 210000003618 cortical neuron Anatomy 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 125000004437 phosphorous atom Chemical group 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 230000002459 sustained effect Effects 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000003371 toe Anatomy 0.000 description 4
- 230000003827 upregulation Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 3
- 206010003571 Astrocytoma Diseases 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102100023733 Ephrin-B3 Human genes 0.000 description 3
- 108010044085 Ephrin-B3 Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 101710203526 Integrase Proteins 0.000 description 3
- 108091092195 Intron Proteins 0.000 description 3
- 208000028389 Nerve injury Diseases 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108020004459 Small interfering RNA Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 108091081024 Start codon Proteins 0.000 description 3
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 238000001516 cell proliferation assay Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000012875 competitive assay Methods 0.000 description 3
- 230000009918 complex formation Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000007877 drug screening Methods 0.000 description 3
- 210000002683 foot Anatomy 0.000 description 3
- 230000030279 gene silencing Effects 0.000 description 3
- 238000012226 gene silencing method Methods 0.000 description 3
- 230000002518 glial effect Effects 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 238000001114 immunoprecipitation Methods 0.000 description 3
- 230000003447 ipsilateral effect Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000008764 nerve damage Effects 0.000 description 3
- 210000004248 oligodendroglia Anatomy 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 3
- 210000002804 pyramidal tract Anatomy 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 210000005250 spinal neuron Anatomy 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000014621 translational initiation Effects 0.000 description 3
- 230000000472 traumatic effect Effects 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- QGZCUOLOTMJILH-UHFFFAOYSA-N 2h-tetrazol-2-ium;bromide Chemical compound [Br-].C1=N[NH+]=NN1 QGZCUOLOTMJILH-UHFFFAOYSA-N 0.000 description 2
- LHYQAEFVHIZFLR-UHFFFAOYSA-L 4-(4-diazonio-3-methoxyphenyl)-2-methoxybenzenediazonium;dichloride Chemical compound [Cl-].[Cl-].C1=C([N+]#N)C(OC)=CC(C=2C=C(OC)C([N+]#N)=CC=2)=C1 LHYQAEFVHIZFLR-UHFFFAOYSA-L 0.000 description 2
- DFVFTMTWCUHJBL-UHFFFAOYSA-N 4-azaniumyl-3-hydroxy-6-methylheptanoate Chemical compound CC(C)CC(N)C(O)CC(O)=O DFVFTMTWCUHJBL-UHFFFAOYSA-N 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 102000005598 Chondroitin Sulfate Proteoglycans Human genes 0.000 description 2
- 108010059480 Chondroitin Sulfate Proteoglycans Proteins 0.000 description 2
- 208000032544 Cicatrix Diseases 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical compound CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 2
- 102100023721 Ephrin-B2 Human genes 0.000 description 2
- 108010044090 Ephrin-B2 Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 2
- 108700011259 MicroRNAs Proteins 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 102000042773 Small Nucleolar RNA Human genes 0.000 description 2
- 108020003224 Small Nucleolar RNA Proteins 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
- 238000012867 alanine scanning Methods 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000021235 carbamoylation Effects 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000005056 cell body Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000009194 climbing Effects 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000005094 computer simulation Methods 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 239000004643 cyanate ester Substances 0.000 description 2
- XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 2
- 230000003436 cytoskeletal effect Effects 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000007783 downstream signaling Effects 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 2
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
- 210000000020 growth cone Anatomy 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 2
- 238000002684 laminectomy Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 210000000274 microglia Anatomy 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 230000004001 molecular interaction Effects 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 230000004766 neurogenesis Effects 0.000 description 2
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- OJUGVDODNPJEEC-UHFFFAOYSA-N phenylglyoxal Chemical compound O=CC(=O)C1=CC=CC=C1 OJUGVDODNPJEEC-UHFFFAOYSA-N 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 230000037387 scars Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000004055 small Interfering RNA Substances 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- NPDBDJFLKKQMCM-SCSAIBSYSA-N (2s)-2-amino-3,3-dimethylbutanoic acid Chemical compound CC(C)(C)[C@H](N)C(O)=O NPDBDJFLKKQMCM-SCSAIBSYSA-N 0.000 description 1
- KMOUUZVZFBCRAM-OLQVQODUSA-N (3as,7ar)-3a,4,7,7a-tetrahydro-2-benzofuran-1,3-dione Chemical compound C1C=CC[C@@H]2C(=O)OC(=O)[C@@H]21 KMOUUZVZFBCRAM-OLQVQODUSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
- KFDPCYZHENQOBV-UHFFFAOYSA-N 2-(bromomethyl)-4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1CBr KFDPCYZHENQOBV-UHFFFAOYSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- 102100027962 2-5A-dependent ribonuclease Human genes 0.000 description 1
- 108010000834 2-5A-dependent ribonuclease Proteins 0.000 description 1
- WTOFYLAWDLQMBZ-UHFFFAOYSA-N 2-azaniumyl-3-thiophen-2-ylpropanoate Chemical compound OC(=O)C(N)CC1=CC=CS1 WTOFYLAWDLQMBZ-UHFFFAOYSA-N 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical compound NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 description 1
- FBTSQILOGYXGMD-LURJTMIESA-N 3-nitro-L-tyrosine Chemical class OC(=O)[C@@H](N)CC1=CC=C(O)C([N+]([O-])=O)=C1 FBTSQILOGYXGMD-LURJTMIESA-N 0.000 description 1
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- 125000000972 4,5-dimethylthiazol-2-yl group Chemical group [H]C([H])([H])C1=C(N=C(*)S1)C([H])([H])[H] 0.000 description 1
- JAJQQUQHMLWDFB-UHFFFAOYSA-N 4-azaniumyl-3-hydroxy-5-phenylpentanoate Chemical compound OC(=O)CC(O)C(N)CC1=CC=CC=C1 JAJQQUQHMLWDFB-UHFFFAOYSA-N 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 208000025940 Back injury Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 1
- 229940123150 Chelating agent Drugs 0.000 description 1
- 235000006481 Colocasia esculenta Nutrition 0.000 description 1
- 240000004270 Colocasia esculenta var. antiquorum Species 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 108091027757 Deoxyribozyme Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 108010055196 EphA2 Receptor Proteins 0.000 description 1
- 108010055191 EphA3 Receptor Proteins 0.000 description 1
- 108010055182 EphA5 Receptor Proteins 0.000 description 1
- 108010055207 EphA6 Receptor Proteins 0.000 description 1
- 108010055153 EphA7 Receptor Proteins 0.000 description 1
- 108010055155 EphA8 Receptor Proteins 0.000 description 1
- 108010055334 EphB2 Receptor Proteins 0.000 description 1
- 102100030322 Ephrin type-A receptor 1 Human genes 0.000 description 1
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 1
- 102100030324 Ephrin type-A receptor 3 Human genes 0.000 description 1
- 102100021605 Ephrin type-A receptor 5 Human genes 0.000 description 1
- 102100021606 Ephrin type-A receptor 7 Human genes 0.000 description 1
- 102100021601 Ephrin type-A receptor 8 Human genes 0.000 description 1
- 102100030779 Ephrin type-B receptor 1 Human genes 0.000 description 1
- 102100031968 Ephrin type-B receptor 2 Human genes 0.000 description 1
- 102100031982 Ephrin type-B receptor 3 Human genes 0.000 description 1
- 102100031983 Ephrin type-B receptor 4 Human genes 0.000 description 1
- 102100031984 Ephrin type-B receptor 6 Human genes 0.000 description 1
- 102100033919 Ephrin-A2 Human genes 0.000 description 1
- 108010043942 Ephrin-A2 Proteins 0.000 description 1
- 102100033940 Ephrin-A3 Human genes 0.000 description 1
- 108010043940 Ephrin-A3 Proteins 0.000 description 1
- 102100033942 Ephrin-A4 Human genes 0.000 description 1
- 108010043938 Ephrin-A4 Proteins 0.000 description 1
- 102100033941 Ephrin-A5 Human genes 0.000 description 1
- 102100033946 Ephrin-B1 Human genes 0.000 description 1
- 108010044099 Ephrin-B1 Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010051815 Glutamyl endopeptidase Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 229940127461 Growth Hormone Receptor Agonists Drugs 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical group C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- 101000938354 Homo sapiens Ephrin type-A receptor 1 Proteins 0.000 description 1
- 101001064150 Homo sapiens Ephrin type-B receptor 1 Proteins 0.000 description 1
- 101001064458 Homo sapiens Ephrin type-B receptor 3 Proteins 0.000 description 1
- 101001064451 Homo sapiens Ephrin type-B receptor 6 Proteins 0.000 description 1
- 101000925251 Homo sapiens Ephrin-A5 Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 102000010410 Nogo Proteins Human genes 0.000 description 1
- 108010077641 Nogo Proteins Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 150000007930 O-acyl isoureas Chemical class 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920006080 Polyloy® Polymers 0.000 description 1
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 102100035124 Rhotekin Human genes 0.000 description 1
- 101710122991 Rhotekin Proteins 0.000 description 1
- 108010057163 Ribonuclease III Proteins 0.000 description 1
- 102000003661 Ribonuclease III Human genes 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 101710204410 Scaffold protein Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- NYTOUQBROMCLBJ-UHFFFAOYSA-N Tetranitromethane Chemical compound [O-][N+](=O)C([N+]([O-])=O)([N+]([O-])=O)[N+]([O-])=O NYTOUQBROMCLBJ-UHFFFAOYSA-N 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000000516 activation analysis Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000005600 alkyl phosphonate group Chemical group 0.000 description 1
- 150000001371 alpha-amino acids Chemical class 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940093740 amino acid and derivative Drugs 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 102000025171 antigen binding proteins Human genes 0.000 description 1
- 108091000831 antigen binding proteins Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- AWGTVRDHKJQFAX-UHFFFAOYSA-M chloro(phenyl)mercury Chemical compound Cl[Hg]C1=CC=CC=C1 AWGTVRDHKJQFAX-UHFFFAOYSA-M 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000000942 confocal micrograph Methods 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 150000001913 cyanates Chemical class 0.000 description 1
- 150000001923 cyclic compounds Chemical class 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 125000004119 disulfanediyl group Chemical group *SS* 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 230000002774 effect on peptide Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229940015043 glyoxal Drugs 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 210000004884 grey matter Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 239000004030 hiv protease inhibitor Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 239000013554 lipid monolayer Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000005230 lumbar spinal cord Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 150000002730 mercury Chemical class 0.000 description 1
- 150000002731 mercury compounds Chemical class 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- SJFKGZZCMREBQH-UHFFFAOYSA-N methyl ethanimidate Chemical compound COC(C)=N SJFKGZZCMREBQH-UHFFFAOYSA-N 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 210000000337 motor cortex Anatomy 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000006218 nasal suppository Substances 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 238000006396 nitration reaction Methods 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000002509 periaqueductal gray Anatomy 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000008196 pharmacological composition Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 108091005981 phosphorylated proteins Proteins 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 230000032361 posttranscriptional gene silencing Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000010979 ruby Substances 0.000 description 1
- 229910001750 ruby Inorganic materials 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 210000004116 schwann cell Anatomy 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 102000030938 small GTPase Human genes 0.000 description 1
- 108060007624 small GTPase Proteins 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000012306 spectroscopic technique Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 125000004646 sulfenyl group Chemical group S(*)* 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 229940126577 synthetic vaccine Drugs 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
本発明は、神経系の障害、特に中枢神経系内のグリオーシス反応および/または炎症反応に関連する障害の治療法と、そのために有用な治療薬に関する。特に、本発明は、神経系への疾患または損傷の間および/または後に起こる、Eph受容体仲介性グリオーシスおよび/もしくはグリア瘢痕および/もしくは炎症および/もしくはEph受容体仲介性の軸索成長阻害を防止する、またはその量を低減させる方法を含む。本発明は、Eph受容体仲介性シグナル伝達を調節する治療薬の同定も促進する。本発明の方法および治療薬は、特に、脳または脊髄への生理的、病理的または外傷による損傷によって誘導される麻痺を含む、一連の神経系の疾患、状態および損傷を治療するために有用である。
本明細書中のいかなる先行技術への参照も、この先行技術が任意の国の共通する一般的知識の一部をなすとの自認または示唆の任意の形であるわけではなく、またそのように理解されるべきではない。
本明細書を通して、文脈からそうではないことが要求されない限り、「含む(comprise)」なる用語や、「含む(comprises)」および「含むこと(comprising)」などの変形は、述べられた整数もしくは段階、または整数もしくは段階群の包含を意味するが、任意の他の整数もしくは段階、または整数もしくは段階群の除外を意味するものではないことが理解されると思われる。
本発明は、疾患または損傷後の中枢神経系内のグリア瘢痕形成はEph受容体、特にEph仲介性シグナル伝達によって仲介されという確認に部分的に基づいている。グリア瘢痕形成はEph受容体によって調節されるとの判断により、疾患もしくは損傷の間またはそれによって生じるものなどの神経系の障害を治療する方法の開発、およびそのために有用な治療薬の開発が促進される。
材料および方法
下記の材料および方法を以下の実施例において用いる。
月齢3〜12ヶ月で以前に記載されたとおり(Coonan et al., J Comp Neurol 436:248-262, 2001)に維持した成獣EphA4-/-およびC57BL/6マウスを本試験で用いた。
マウスをケタミンおよびキシラジンの混合物(それぞれ100mg/kgおよび16mg/kg)で麻酔した。脊髄を椎弓切除術により曝露し、腰膨大のレベルに対応するT12〜L1レベルで2〜3の椎弓を切除した。T12で脊髄左半側切断を細い角膜刃を用いて行い(同じ場所を二回切り、完全切断を確認した)、重なる筋肉および皮膚を縫合した。半側切断を野生型44匹およびEphA4-/-マウス37匹で行った。これらのうち、野生型28匹およびEphA4-/-マウス19匹を用いて免疫組織化学検査を行った。残りのマウスは行動を評価し、続いて軸索トレーシングにより再生の程度を調べた。
脊髄損傷の5週間後、テトラメチルローダミンデキストラン(「Fluoro-Ruby」、分子量10,000kD)を脊髄に損傷と同側の頸膨大のレベルで、ハミルトンシリンジに連結したガラスピペットから注入した。さらに7日間の生存期間の後、マウスに4%パラホルムアルデヒドを灌流した。凍結ミクロトーム上で脊髄の縦の連続切片を50μmで切断し、切片をゼラチン化スライドに固定し、蛍光および共焦点顕微鏡を用いて検査した。
傷害下の腰髄を腰椎下部椎弓切除術により曝露した。注射により損傷された軸索のニューロン細胞体を標識するFast Blue(2%w/v、注入一回あたり0.3μl;EMS-POLYLOY GmBH,Grobβ-Umstadt, Germany)を、傷害部位の同側の脊髄に、ハミルトンシリンジに連結したガラスマイクロピペットで注入した。5日間の生存期間の後、マウスにPBS中の4%パラホルムアルデヒドを灌流した。脳および脊髄を摘出し、固定液中20%スクロース中で24時間後固定した後、凍結ミクロトーム上、冠/横断面で50μmで連続切断した。処置した脊髄縦切片において一側性の注入部位を確認したことから、注入は成功したと考えられた。コンピューター接続デジタル化システム(MD3顕微鏡ディジタイザーおよびMD-プロットソフトウェア;Minnesota Datametrics Corporation, MN, USA)を用い、一連の切片4枚毎に標識細胞の位置をマッピングすることにより、標識ニューロンの定性的および定量的比較を行った。
歩幅:半側切断の前後に、マウスの後ろ足に非毒性インクを塗布し、ブロッティング紙上のトンネル内に置くことにより足形を取った(野生型n=7、EphA4-/- n=9)。歩幅を、複数の連続する足跡の測定によりもとめ、結果を各マウスの基準時歩幅のパーセンテージとして表した。
ウサギ抗-GFAP(1:500、Dako)、マウス抗-CSPG(1:200、Sigma)およびウサギ抗-EphA4を用いた標準免疫組織化学法を行った。ウサギ抗-EphA4抗体(発明者らから入手可能)を、標準法(Cooper and Paterson, Current protocols in molecular biology, eds Ausubel et al. 11.12.11-11.12.19, John Wiley & Sons, New York, 2000)を用いてEphA4の細胞内SAMドメイン(Genbankアクセッション番号NM007936)のアミノ酸938〜953に対応するペプチドに対して調製した。肥大性星状細胞の数、ならびにGFAP-発現星状細胞の総数を、連続する縦8μm切片3つ毎に、傷害部位およびその2.5mm近位の0.25mm2格子内で計数した。肥大性星状細胞は大きい細胞体と複数の厚く長い突起を有する、強く染色されたGFAP-陽性細胞と定義された。非肥大性星状細胞はGFAPに対して染色強度が低く、小さい細胞体と薄く、複雑でない突起を有していた。肥大性星状細胞は非肥大性星状細胞のサイズの二倍よりも大きかった。
精製した星状細胞およびニューロン培養物を、以前に記載されたとおり(Turnley et al., Nat Neurosci 5:1155-1162, 2002)に調製した。神経突起の長さを分析するために、E16皮質ニューロンを、野生型もしくはEphA4-/-星状細胞単層を含む、またはポリーDL-オルニチン/ラミニンコーティングされたチャンバースライド(Falcon、USA)中5,000/ウェルで播種した。いくつかの実験において、星状細胞を単量体エフリンA5-Fc(0.15、1.5、10μg/ml)または複合エフリンA5-Fc(1.5μg/ml、添加前に0.15μg/ml抗ヒトIgG(Vector)と室温で30分間複合)で1時間前処理した。22時間後、細胞を固定し、神経突起マーカーβIII-チューブリン(1:2000、Promega)について免疫染色した。神経突起の長さを、以前(Turnley et al., Neuroreport 9:1987-1990, 1998)と同様に画像分析を用いて測定した。神経突起の長さの平均における差の有意性をスチューデントt検定を用いて解析した。
細胞を溶解し、試料を全タンパク質レベルの分析のために取っておいた。溶解産物の残りはEphA4またはRho活性化分析における免疫沈降のために用いた。EphA4活性化は、抗ホスホチロシン(Cell Signaling)を用いたリン酸化タンパク質の免疫沈降と、続くウェスタン転写およびウサギ抗EphA4抗体(Dr. D. Wilkinson, National Institute for Medical Research, Londonの厚意により提供を受けた)を用いた活性化または全EphA4の検出により評価した。Rho活性化アッセイは、Rhotekin RBDアッセイを製造者(Upstate、USA)の指示に従い用いて行った。全EphA4およびβ-アクチン発現レベルを、非傷害および傷害から7日後の脊髄で、前述のウサギ抗EphA4抗体およびマウス抗β-アクチン抗体(Sigma)を用いたウェスタン分析により評価した。濃度測定をNIH Imageソフトウェアを用いたオートラジオグラフで実施し、EphA4バンドの相対レベルをもとめ、β-アクチンレベルに標準化した。
臭化[3-(4,5-ジメチルチアゾル-2-イル)-2,5-ジフェニル]テトラゾリウム(MTT)アッセイは、生存細胞中のミトコンドリア活性を測定するもので、増殖アッセイとしてよく用いられる(Mosmann, J Immunol Methods 65:55-63, 1983)。生存細胞はテトラゾリウム環を暗青色のホルマザン結晶に変換し、これは光学密度(O.D.)を読み取ることにより定量することができる;O.D.の増大は経時的な細胞数の増加に相関している。野生型およびEphA4-/-星状細胞を、96穴プレート(Falcon)で、10%FCSを補足したDMEM中、LIF(1000U/ml)またはIFN-γ(100U/ml)いずれかの存在下、または非存在下、3×103細胞/ウェルで播種した。MTTアッセイを播種の2、24、48および72時間後に実施した。MTT(0.25mg/ml)を各時点の細胞と共に37℃で2時間インキュベートし、次いで細胞を等量の酸性イソプロパノール(無水イソプロパノール中0.04M HCL)で溶解し、ホルマザン生成物のO.D.を550〜650nmで測定した。
PBS/エフリンA5-Fc(0.687mg/注射)またはPBS単独の注射を、手術後2時間で開始し、次いで24時間毎に2週間までI.P.で行った。
傷害軸索のトレーシングは6週間までに大規模な再生を示す
EphA4-/-マウスはいくらかの発生皮質脊髄路異常を有し、一部の軸索は早期停止するか、または中線を異常に交差するため(Dottori et al., Proc Natl Acad Sci USA 95:13248-13253, 1998;Coonan et al., J Comp Neurol 436:248-262, 2001)、標準の皮質脊髄路トレーシング技術の使用は不可能である。加えて、発明者らは他の軸索路におけるEphA4欠失の影響に関する仮説を立てようと考えなかった。したがって、発明者らは順行性トレーシング技術の利用を選択し、それによりトレーサーを腰の傷害部位よりもずっと上部の頸髄に注入した。これにより、個々の軸索の全般的再生を評価することが可能となった。非傷害野生型およびEphA4-/-マウスでこの技術を用いることにより、注入部位と同側の下行軸索経路の同等の標識が見られたが、注入部位と反対側では標識は見られなかった。
EphA4-/-マウスの機能回復
EphA4-/-マウスで観察された軸索再生は機能的相関も有していた。マウスを、まず脊髄半側切断の前および24時間から4週間後に歩幅を測定することにより(Bregman et al., Nature 378:498-501, 1995)、行動評価した。24時間の時点で、EphA4-/-および野生型マウスはいずれも最小の機能を示した。EphA4-/-マウスは3週間以内にその基準時の歩幅の100%を回復したが、野生型マウスは70%の回復しか示さず(図3d)、その後も改善しなかった。加えて、半側切断の1ヶ月後、同側の後足握力(図3e)および格子上を歩く能力(図3f)はEphA4-/-マウスでは野生型に比べて劇的に改善した。これらの機能は傷害後3ヶ月まで改善し続けた。非傷害EphA4-/-マウスおよび野生型マウスはいずれもこれらの試験で最高の点数を達成した。
EphA4-/-マウスにおける星状細胞グリオーシスの欠損
半側切断EphA4-/-脊髄の著しい特徴は、GFAP発現により評価して、野生型に比べ星状細胞グリオーシスが実質的にないことであった(図4a、b、d、e)。第7日の時点で、野生型傷害部位のGFAP-陽性星状細胞の大多数(90.4%)は肥大性で、GFAPについて非常に強く染色されたが、EphA4-/-星状細胞では7.4%だけが肥大性であった(図4g)。全体に見て、GFAP陽性細胞の総数は傷害後の最初の7日間を通してEphA4-/-半側切断で少なく、これは傷害部位の近位で著しい(図4h)。非傷害例において、EphA4-/-および野生型マウス間で星状細胞数に差はなかった(EphA4-/-の825.6±98.1/mm2に比べて野生型836.8±108.3/mm2)。グリア反応がないことで、グリア瘢痕の成分であるCSPGの免疫染色により評価して、EphA4-/-マウスでは傷害の6週間後にグリア瘢痕のサイズの著しい低下が見られた(図4c、f)。
星状細胞上のEphA4発現は神経突起増殖を阻害する
星状細胞上のEphA4発現を、これがインビトロで皮質ニューロンの神経突起増殖を阻害するかどうかについて調べた。E16皮質ニューロンを野生型またはEphA4-/-星状細胞いずれかの単層上に播種し、22時間後に最も長い神経突起の長さを測定した。これにより、野生型星状細胞に比べてEphA4-/-星状細胞上で増殖の2〜3倍の増大が明らかとなった(図5e〜g)。ニューロンをEphA4を形質移入された293T細胞上で増殖させた場合にも同様の結果が得られた(非形質移入293T細胞上の神経突起の長さは80.4±3.3μmであったのに比べて、EphA4を形質移入した細胞上では30.2±1.9μm)ため、この効果は星状細胞上のEphA4の発現に直接起因すると考えられた。野生型およびEphA4-/-星状細胞の両方における、野生型ニューロンに比べてEphA4-/-ニューロンの神経突起増殖増大(図5g)は、以前に示唆されているとおり(Wahl et al., J Cell Biol 149:263-270、2000;Kullander et al., Genes Dev 15:877-888, 2001)ニューロン上で発現されたEphA4も神経突起増殖を阻害し、EphA4-/-マウスで観察される再生に寄与していることを示唆している。星状細胞上での神経突起増殖の阻害は、星状細胞単層においてEphA4に強く結合する、単量体エフリンA5-Fcの添加により用量依存的様式で強力に阻止されたが、ラミニンコーティングしたガラススライド上で増殖したニューロンには何の影響も無かった(図5h)。反対に、以前に記載されたとおり(Wahl et al., J Cell Biol 149:263-270, 2000;Kullander et al., Genes Dev 15:877-888, 2001)、複合エフリンA5-Fcの添加はガラススライド上で神経突起増殖を阻害し、星状細胞上で増殖をさらに阻害した(図5h)。これは、星状細胞上のEphA4の阻止は神経突起増殖を増強するが、ニューロン上ではそのような効果は見られず、一方でニューロンおよび星状細胞両方におけるEphA4の活性化は神経突起増殖を阻害することを示している。これらの結果はいずれも、リガンドによるEphA4の活性化が神経突起阻害のメカニズムであることを直接示すものである。インビボで、星状細胞上のEphA4発現に対する神経突起反応の活性化物質の可能性があるものはエフリンB3で、これはシグナルを変換することが示されており(Palmer et al., Mol Cell 9:725-737, 2002)、脊髄における再生中の軸索によって発現された。
Rho活性化および増殖はEphA4-/-星状細胞において低減させる
以前の試験が、グリオーシスはインターフェロン-γ(IFNγ)および白血病阻害因子(LIF)を含む炎症サイトカインによって仲介されると示している(Yong et al., Proc Natl Acad Sci USA 88:7016-7020, 1991;Balasingam et al., J Neurosci 14:846-856, 1994;Sugiura et al., Eur J Neurosci 12:457-466, 2000)ことを考慮して、発明者らはこれらのサイトカインが星状細胞上のEphA4のアップレギュレーションにおいて役割を果たしているかどうかを調べた。IFNγおよびLIFはEphA4発現をそれぞれ56%および69%アップレギュレートしたが、インターロイキン-1(Il-1)および腫瘍壊死因子-α(TNFα)は効果がなかった(図6a)。EphA4発現が星状細胞反応につながりうる下流活性化を伴うかどうかの疑問に直接取り組むため、発明者らはEphA4がリン酸化されるかどうかを調べた。IFNγおよびLIFはいずれも、可溶性多量体EphA4リガンドであるエフリンA5-Fcの添加と同様の様式で、EphA4リン酸化を2倍アップレギュレートした(図6a)。加えて、これは、Eph受容体シグナル伝達の下流の細胞骨格変化の主な調節物質である、低分子GTPアーゼ、Rho(Hall, Science 279:509-514, 1998)の活性化における著しい増加を引き起こした(Wahl et al., J Cell Biol 149:263-270, 2000;Shamah et al., Cell 105:233-244, 2001)。Rho活性化増大は傷害部位から摘出した野生型脊髄組織(図6b)および培養星状細胞(図6c)の両方で起こったが、傷害EphA4-/-動物から摘出した細胞または組織を用いて、そのような反応は観察されなかった。星状細胞、ならびにニューロンおよび乏突起膠細胞におけるRhoの活性化も、損傷後の脊髄において最近報告されている(Dubreuil et al., J Cell Biol 162:233-243, 2003)。
エフリンA5-Fcの注射は軸索再生を増大させる
単量体エフリンA5-FcはインビトロでEphA4の活性化を阻止する。エフリンA5-Fc注射後、脊髄傷害を受けたマウスの星状細胞グリオーシスは、PBS単独を注射したものに比べて、有意に低減する(図7Aおよび7B)。同様に、2週間のエフリンA5-Fc注射も損傷脊髄におけるEphA4アップレギュレーションを阻害する(図8)。傷害から2週間後のマウスの脊髄で軸索再生を調べる場合、PBS単独(図10)に比べてエフリンA5-Fc注射後(図9)に、傷害部位付近の有意な側枝出芽および再生が起こる。この再生はSCIおよびエフリンA5-Fc注射を受けたマウスの格子歩行およびよじ登りにおける有意な改善に反映される(図11)。SCIの6週間後、傷害部位をまたがる有意な軸索再生がエフリンA5-Fcを注射されたマウスで観察される(図12)。
Claims (47)
- 対象の神経系内のグリオーシスおよび/もしくはグリア瘢痕および/もしくは炎症および/もしくは軸索成長阻害を防止する、またはその量を低減させる方法であって、Eph受容体仲介性シグナル伝達のレベルを低下させるために、対象にEph受容体のレベルおよび/もしくは機能、またはEph受容体機能に必要とされる分子を低減させる物質を投与する段階を含む方法。
- Eph受容体がEphA4受容体またはそのホモログ、パラログ、オルソログ、誘導体、もしくは機能的等価物である、請求項1記載の方法。
- Eph受容体がEphA4受容体である、請求項2記載の方法。
- 物質がタンパク質性または非タンパク質性分子である、請求項1または2または3記載の方法。
- 物質がEphA4受容体アンタゴニスト、ホモログ、類縁体、誘導体、または構造類似物質である、請求項4記載の方法。
- 物質がエフリンアンタゴニスト、ホモログ、類縁体、誘導体、または構造類似物質である、請求項4記載の方法。
- 物質が核酸分子である、請求項4記載の方法。
- 核酸分子がEphA4受容体mRNA転写物に対するアンチセンス、センス、DNA由来RNAiまたは合成RNAiである、請求項7記載の方法。
- 物質が抗体またはその誘導体、組換え体、キメラ型、もしくは脱免疫化型(deimmunized form)である、請求項4記載の方法。
- 神経系が中枢神経系(CNS)である、請求項1記載の方法。
- 対象がヒトである、請求項1記載の方法。
- 物質の有効性を測定する方法であって、実験対象の中枢神経系を傷害する段階と、試験する物質を傷害中枢神経系にその物質の有効性を評価するのに適した期間および条件下で投与する段階と、次いで一定期間後に中枢神経系傷害の部位でグリオーシスおよび/またはグリア瘢痕および/または炎症および/または軸索再生成長のレベルを評価する段階とを含む方法。
- 傷害される中枢神経系が脊髄である、請求項12記載の方法。
- 物質がEph受容体またはEph受容体仲介性シグナル伝達を阻害する、請求項12または13記載の方法。
- Eph受容体がEphA4またはそのホモログ、パラログ、オルソログ、誘導体、もしくは機能的等価物である、請求項14記載の方法。
- Eph受容体がEphA4受容体である、請求項15記載の方法。
- 物質がタンパク質性または非タンパク質性分子である、請求項12または13または14または15記載の方法。
- 物質がEphA4アンタゴニスト、ホモログ、類縁体、誘導体、または構造類似物質である、請求項17記載の方法。
- 物質がエフリンアンタゴニスト、ホモログ、類縁体、誘導体、または構造類似物質である、請求項17記載の方法。
- 物質が核酸分子である、請求項17記載の方法。
- 核酸分子がEphA4受容体mRNA転写物に対するアンチセンス、センス、DNA由来RNAiまたは合成RNAiである、請求項20記載の方法。
- 物質が抗体またはその誘導体、組換え体、キメラ型、もしくは脱免疫化型である、請求項17記載の方法。
- 神経系が中枢神経系(CNS)である、請求項12記載の方法。
- 対象がヒトである、請求項12記載の方法。
- 物質の有効性を測定する方法であって、細胞を試験する物質とインビトロで該物質の有効性を評価するのに適した期間および条件下で接触させる段階と、次いで一定期間後にグリオーシスおよび/またはグリア瘢痕および/または炎症および/または軸索再生に関与する細胞の性向を評価する段階とを含む方法。
- 物質がEph受容体またはEph受容体仲介性シグナル伝達を阻害する、請求項25記載の方法。
- Eph受容体がEphA4またはそのホモログ、パラログ、オルソログ、誘導体、もしくは機能的等価物である、請求項25記載の方法。
- Eph受容体がEphA4受容体である、請求項27記載の方法。
- 物質がタンパク質性または非タンパク質性分子である、請求項25または26または27または28記載の方法。
- 物質がEphA4アンタゴニスト、ホモログ、類縁体、誘導体、または構造類似物質である、請求項29記載の方法。
- 物質がエフリンアンタゴニスト、ホモログ、類縁体、誘導体、または構造類似物質である、請求項29記載の方法。
- 物質が核酸分子である、請求項29記載の方法。
- 核酸分子がEphA4受容体mRNA転写物に対するアンチセンス、センス、DNA由来RNAiまたは合成RNAiである、請求項32記載の方法。
- 物質が抗体またはその誘導体、組換え体、キメラ型、もしくは脱免疫化型である、請求項29記載の方法。
- 対象の神経系内のグリオーシスおよび/もしくはグリア瘢痕および/もしくは炎症を防止する、またはその量を低減させる方法であって、該対象にEphA4仲介性シグナル伝達のアンタゴニストの有効量をグリオーシスおよび/もしくはグリア瘢痕および/もしくは炎症を防止または低減させるのに十分な期間および条件下で投与する段階を含む方法。
- Eph受容体がEphA4受容体である、請求項35記載の方法。
- 物質がタンパク質性または非タンパク質性分子である、請求項36記載の方法。
- 物質がEphA4アンタゴニスト、ホモログ、類縁体、誘導体、または構造類似物質である、請求項35記載の方法。
- 物質がエフリンアンタゴニスト、ホモログ、類縁体、誘導体、または構造類似物質である、請求項35記載の方法。
- 物質が核酸分子である、請求項35記載の方法。
- 核酸分子がEphA4受容体mRNA転写物に対するアンチセンス、センス、DNA由来RNAiまたは合成RNAiである、請求項39記載の方法。
- 物質が抗体またはその誘導体、組換え体、キメラ型、もしくは脱免疫化型である、請求項35記載の方法。
- 神経系が中枢神経系(CNS)である、請求項35記載の方法。
- 対象がヒトである、請求項35記載の方法。
- グリオーシスおよび/またはグリア瘢痕および/または炎症を低減させる際に用いるためのEphA4仲介性シグナル伝達のアンタゴニストである単離物質。
- 請求項44記載の物質と一つまたは複数の薬学的に許容される担体および/または希釈剤および/または賦形剤とを含む薬学的組成物。
- グリオーシスおよび/またはグリア瘢痕および/または炎症の防止のための医用薬剤製造におけるEph受容体の使用。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2004905148 | 2004-09-08 | ||
AU2004905148A AU2004905148A0 (en) | 2004-09-08 | A method of treatment and agents useful for same | |
US64796805P | 2005-01-27 | 2005-01-27 | |
US60/647,968 | 2005-01-27 | ||
PCT/AU2005/001363 WO2006026820A1 (en) | 2004-09-08 | 2005-09-08 | Treating gliosis, glial scarring, inflammation or inhibition of axonal growth in the nervous system by modulating eph receptor |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012030227A Division JP2012136529A (ja) | 2004-09-08 | 2012-02-15 | Eph受容体を調節することによる神経系内のグリオーシス、グリア瘢痕、炎症、または軸索成長阻害の処置 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2008512394A true JP2008512394A (ja) | 2008-04-24 |
JP2008512394A5 JP2008512394A5 (ja) | 2008-10-09 |
JP5094395B2 JP5094395B2 (ja) | 2012-12-12 |
Family
ID=36036018
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007530543A Expired - Fee Related JP5094395B2 (ja) | 2004-09-08 | 2005-09-08 | Eph受容体を調節することによる神経系内のグリオーシス、グリア瘢痕、炎症、または軸索成長阻害の処置 |
JP2012030227A Withdrawn JP2012136529A (ja) | 2004-09-08 | 2012-02-15 | Eph受容体を調節することによる神経系内のグリオーシス、グリア瘢痕、炎症、または軸索成長阻害の処置 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012030227A Withdrawn JP2012136529A (ja) | 2004-09-08 | 2012-02-15 | Eph受容体を調節することによる神経系内のグリオーシス、グリア瘢痕、炎症、または軸索成長阻害の処置 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20080254023A1 (ja) |
EP (1) | EP1793854A4 (ja) |
JP (2) | JP5094395B2 (ja) |
CA (1) | CA2579352A1 (ja) |
NZ (1) | NZ553273A (ja) |
WO (1) | WO2006026820A1 (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPP674898A0 (en) | 1998-10-27 | 1998-11-19 | Walter And Eliza Hall Institute Of Medical Research, The | A method of treatment |
NZ553273A (en) * | 2004-09-08 | 2009-11-27 | Univ Melbourne | Treating gliosis, glial scarring, inflammation or inhibition of a xonal growth in the nervous system with an antagonist of EphA4-mediated signalling |
KR20090029261A (ko) * | 2006-07-13 | 2009-03-20 | 노파르티스 아게 | 신경계 장애의 치료에서의 트리플루오로메틸-치환 벤즈아미드의 용도 |
US8530181B2 (en) | 2007-11-15 | 2013-09-10 | Eisai R&D Management Co., Ltd. | Method of screening for compounds which affect the cleavage of EphA7 byγ-secretase |
EP2223999B1 (en) * | 2007-11-30 | 2017-10-18 | Eisai R&D Management Co., Ltd. | Epha4 polypeptide having novel activity and use thereof |
EP2260864A1 (en) * | 2009-06-10 | 2010-12-15 | University of Melbourne | Therapeutic applications |
US8865426B2 (en) | 2010-12-17 | 2014-10-21 | Eisai R&D Management Co., Ltd. | Screening method using gelatinase-mediated EphA4 cleavage reaction as an indicator |
US9784751B2 (en) | 2011-04-25 | 2017-10-10 | Eisai R&D Management Co., Ltd. | Method for detecting neurological disease associated with cognitive impairment by measuring EphA4 extracellular domain |
EP3169344B1 (en) | 2014-07-15 | 2021-09-29 | Sanford Burnham Prebys Medical Discovery Institute | Epha4 cyclic peptide antagonists for neuroprotection and neural repair |
RU2651756C1 (ru) * | 2017-05-10 | 2018-04-23 | Федеральное государственное бюджетное образовательное учреждение Высшего Образования Кубанский Государственный Медицинский Университет Министерства Здравоохранения Российской Федерации, КубГМУ | Препарат для предотвращения образования глиальных рубцов |
MX2021015298A (es) | 2019-07-01 | 2022-01-18 | Eisai R&D Man Co Ltd | Anticuerpo anti-epha4 humano. |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000024413A1 (en) * | 1998-10-27 | 2000-05-04 | The Walter And Eliza Hall Institute Of Medical Research | A method of treatment |
WO2004028551A1 (en) * | 2002-09-24 | 2004-04-08 | The Burnham Institute | Novel agents that modulate eph receptor activity |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2242437T3 (es) * | 1998-11-20 | 2005-11-01 | Genentech, Inc. | Utilizaciones de agonistas y antagonistas del receptor eph para el tratamiento de trastornos vasculares. |
AU2003287424A1 (en) * | 2002-11-01 | 2004-06-07 | Case Western Reserve University | Methods of inhibiting glial scar formation |
WO2005056766A2 (en) * | 2003-12-04 | 2005-06-23 | Medimmune, Inc. | TARGETED DRUG DELIVERY USING EphA2 OR Eph4 BINDING MOIETIES |
NZ553273A (en) * | 2004-09-08 | 2009-11-27 | Univ Melbourne | Treating gliosis, glial scarring, inflammation or inhibition of a xonal growth in the nervous system with an antagonist of EphA4-mediated signalling |
-
2005
- 2005-09-08 NZ NZ553273A patent/NZ553273A/en not_active IP Right Cessation
- 2005-09-08 EP EP05778955A patent/EP1793854A4/en not_active Withdrawn
- 2005-09-08 CA CA002579352A patent/CA2579352A1/en not_active Abandoned
- 2005-09-08 US US11/662,355 patent/US20080254023A1/en not_active Abandoned
- 2005-09-08 JP JP2007530543A patent/JP5094395B2/ja not_active Expired - Fee Related
- 2005-09-08 WO PCT/AU2005/001363 patent/WO2006026820A1/en active Application Filing
-
2012
- 2012-02-15 JP JP2012030227A patent/JP2012136529A/ja not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000024413A1 (en) * | 1998-10-27 | 2000-05-04 | The Walter And Eliza Hall Institute Of Medical Research | A method of treatment |
WO2004028551A1 (en) * | 2002-09-24 | 2004-04-08 | The Burnham Institute | Novel agents that modulate eph receptor activity |
Also Published As
Publication number | Publication date |
---|---|
WO2006026820A9 (en) | 2007-04-05 |
NZ553273A (en) | 2009-11-27 |
EP1793854A4 (en) | 2008-01-02 |
CA2579352A1 (en) | 2006-03-16 |
JP5094395B2 (ja) | 2012-12-12 |
JP2012136529A (ja) | 2012-07-19 |
EP1793854A1 (en) | 2007-06-13 |
US20080254023A1 (en) | 2008-10-16 |
WO2006026820A1 (en) | 2006-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5094395B2 (ja) | Eph受容体を調節することによる神経系内のグリオーシス、グリア瘢痕、炎症、または軸索成長阻害の処置 | |
JP5829373B2 (ja) | Nogoレセプターアンタゴニスト | |
KR101239542B1 (ko) | 탈수초화를 수반하는 병의 치료 | |
JP5060293B2 (ja) | 神経機能におけるtaj | |
KR101106441B1 (ko) | 노고 수용체 결합 단백질 | |
JP6046493B2 (ja) | プロミニン−1の血管新生促進フラグメントおよびその使用 | |
Kubo et al. | Rho-ROCK inhibitors for the treatment of CNS injury | |
JP2009517340A (ja) | ドーパミン作動性ニューロンの神経突起成長および生存を促進するための方法 | |
CA2910652C (en) | Tafa4 compounds and uses thereof for treating pain | |
JP2024026109A (ja) | 疼痛を治療し、疼痛感受性を増大させるためのペプチド及び他の薬剤 | |
EP2904009B1 (en) | Compounds for treating the remyelination blockade in diseases associated with the expression of herv-w envelope protein | |
JP5026083B2 (ja) | 神経再生ペプチド及び脳損傷治療におけるそれらの使用方法 | |
JP2002526098A (ja) | 新規なぺプチド類 | |
JP4778507B2 (ja) | 化学療法誘発末梢性ニューロパシーの治療のためのil6r/il6キメラ | |
US20080305078A1 (en) | Soluble Il-17Rc Variant and Uses Thereof | |
AU2005282217B2 (en) | Treating gliosis, glial scarring, inflammation or inhibition of axonal growth in the nervous system by modulating eph receptor | |
US20040009899A1 (en) | Treating dominant disorders | |
KR20100136633A (ko) | 개의 베타-신경 성장 인자 및 이를 함유하는 개의 신경손상 관련 질환 치료용 수의학적 조성물 | |
WO2013049026A2 (en) | Neurabin scaffolding of the adenosine receptor and rgs4 regulates anti-seizure effect of endogenous adenosine | |
KR20100132869A (ko) | 치료적 이용 방법 | |
MX2008009620A (es) | Antagonistas de receptores de nogo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080825 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080825 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110815 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111115 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111122 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120215 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120409 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120629 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20120713 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120820 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120918 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150928 Year of fee payment: 3 |
|
LAPS | Cancellation because of no payment of annual fees |